Lv73
3670 积分 2021-09-26 加入
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)
8天前
已完结
TYRA-200: Potent Against FGFR2 Fusions, Molecular Brake Mutations and Gatekeeper Resistance
13天前
已完结
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
16天前
已完结
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
28天前
已完结
Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia
1个月前
已完结
A comprehensive map of molecular drug targets
2个月前
已完结
Novel drug targets in 2024
2个月前
已完结
New treatments in atopic dermatitis
2个月前
已完结
Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis
2个月前
已完结
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation
2个月前
已完结
皖公网安备34019202002308
